The enemy
who became a hero.
Vyro is a biotechnology company focused on developing oncolytic viruses,
in other words, cancer-killing viruses to attack central nervous system tumors
in adults and children.
Founded by scientists from the Human Genome and Stem Cell Research Center (HUG-CELL) of the University of Sao Paulo, who are now part of the Vyro Biotherapeutics team and who carry out tests based on pioneering research on the oncolytic properties of the Zika virus.
Malignant Central Nervous System tumors
A huge unmet medical need
According to the Central Brain Tumor Registry of the United States, nearly 26,000 new cases of malignant Central Nervous System tumors will be diagnosed in the United States in 2022 alone.
Source: CBTRUS
Rate
of mortality
of tumors
Malignant Central nervous system tumors are considered incurable. The survival prognosis of diagnosed patients rarely exceeds one year.
15%
Breast cancer
14%
Prostate cancer
76%
Malignant Central Nervous System tumors
Malignant central nervous system tumors accounted for 1.3% of new cancer diagnoses in the last 12 months in the United States.
Source: National Cancer Institute
Pediatric Malignant
Central Nervous
System tumors
According to the Central Brain Tumor Registry of the United States, nearly 5,000 cases of pediatric malignant central nervous system tumors will be diagnosed in the United States in 2022.
Source: CBTRUS
Malignant Central Nervous System tumors has overtaken leukemia as the deadliest form of childhood cancer, which is considered the deadliest disease among children under the age of 15.
Source: National Cancer Institute
Even so, there has never been an effective drug developed and approved specifically for Malignant Central Nervous System tumors.
